

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 1093)

VOLUNTARY ANNOUNCEMENT

CPO301 OBTAINS CLINICAL TRIAL APPROVAL IN CANADA

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the Clinical Trial Application for CPO301, a first-in-class antibody drug conjugate developed by the Group, has been approved by Health Canada. The approved study is a multicenter, first-in-human, dose escalation and dose expansion Phase I clinical trial to evaluate the safety, pharmacokinetics and preliminary efficacy of CPO301 in advanced solid tumors including non-small cell lung cancer (NSCLC).

This is the first effort of the Group expanding its global clinical development into Canada, leveraging similarity in cancer treatment and synergy in patient recruitment in North America (U.S. and Canada) towards the expedited development of this important program. Nonclinical studies conducted by the Group have demonstrated highly promising anti-tumor activity of CPO301 in tumor models derived from patients resistant to third-generation EGFR inhibitor Osimertinib.

By order of the board
CSPC Pharmaceutical Group Limited
CAI Dongchen
Chairman

Hong Kong, 8 June 2023

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. WANG Qingxi, Mr. CHAK Kin Man and Dr. JIANG Hao as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive directors.